Who Paid My Doc
Paola Lichtenberger
Infectious Disease Miami, FL Medical Doctor
NPI 1982862744 CMS profile 818451
1611 Nw 12Th Ave, Miami, FL 33136
General payments
$2,200
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$27,853
Through program year 2024, Paola Lichtenberger of Miami, FL is reported in the CMS Open Payments database as having received $2,200 across 1 general payment and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $27,853 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 73rd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $2,200 | 1 |
Beside peers
- Paola Lichtenberger
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Paola Lichtenberger were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Paola Lichtenberger | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $190 | $60–$862 | $163 |
| 2020 | $0 | $124 | $32–$606 | $114 |
| 2021 | $0 | $148 | $38–$905 | $132 |
| 2022 | $0 | $166 | $50–$834 | $149 |
| 2023 | $0 | $171 | $57–$787 | $160 |
| 2024 | $2,200 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 3 billing codesPaid by Medicare
$3,792
Medicare patients
23
Services billed
47
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Depression | 74% | |
| Diabetes | 65% | |
| Arthritis | 61% | |
| Chronic kidney disease | 52% | |
| COPD | 52% | |
| Alzheimer's or dementia | 48% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Florida
Lennox Archibald
Infectious Disease · Gainesville, FL
Moti Ramgopal
Infectious Disease · Fort Pierce, FL
Juan Diaz
Infectious Disease · Altamonte Springs, FL
Charlotte-Paige Rolle
Infectious Disease · Orlando, FL
Kenneth Alexander
Infectious Disease · Orlando, FL
Douglas Brust
Infectious Disease · Miami, FL
Related records
Infectious Disease in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.